Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting

Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive, HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting

Hikmat Abdel-Razeq,1,2 Baha’ Sharaf1 1Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan; 2School of Medicine, The University of Jordan, Amman, JordanCorrespondence: Hikmat Abdel-Razeq, Department of Internal Medicine, King Hussein Cancer Center, Queen Rania Al Abdullah Stree...

Full description

Bibliographic Details
Main Authors: Abdel-Razeq H, Sharaf B
Format: Article
Language:English
Published: Dove Medical Press 2022-03-01
Series:Drug Design, Development and Therapy
Subjects:
cdk4/6 inhibitors
ribociclib
palbociclib
abemaciclib
early-stage breast cancer
adjuvant
Online Access:https://www.dovepress.com/expanding-the-clinical-use-of-cdk46-inhibitors-in-the-treatment-of-hor-peer-reviewed-fulltext-article-DDDT

Internet

https://www.dovepress.com/expanding-the-clinical-use-of-cdk46-inhibitors-in-the-treatment-of-hor-peer-reviewed-fulltext-article-DDDT

Similar Items